Management of acute loss of asthma control: yellow zone strategies.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
17
1
2019
medline:
17
3
2020
entrez:
17
1
2019
Statut:
ppublish
Résumé
Asthma exacerbations are associated with a significant burden to both the individual patient and to the healthcare system. Patients often step-up home therapies in response to increased asthma symptoms, and the asthma action plan was created to empower patients to self-manage their asthma care. The yellow (intermediate) zone of the asthma action plan is frequently poorly defined, and current Expert Panel Report 3 guideline recommendations are not effective for all patients. This article reviews the evidence behind various recommended yellow zone intervention strategies. There are many potential methods of delivering yellow zone therapy, and recent studies have assessed preventive efficacy of a scheduled increase in controller medication(s), reliever medication(s), or a symptom-driven combination of both. The literature suggests that, in certain asthma subpopulations, some methods may be more efficacious than others. Multiple yellow zone approaches may be beneficial, and the yellow zone is not a 'one size fits all' narrative.
Identifiants
pubmed: 30649012
doi: 10.1097/ACI.0000000000000512
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Drug Combinations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM